Breaking News Headlines Today | Ground News

Cyber Week Sale - Get 40% off Vantage

miltonindependent.com image

News from miltonindependent.com

Milton, United States

We’ve assigned a media bias rating of unknown to miltonindependent.com. You can read more about our methodology here.

Is miltonindependent.com credible or reliable? Our Factuality score answers both of those questions. When it comes to miltonindependent.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about miltonindependent.com

Where is miltonindependent.com located?Milton, United Statesmiltonindependent.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top miltonindependent.com News

MENU - ORDER AI Announces Global Expansion with New Multilingual Capabilities, Supporting WHO Guidance on Dietary Needs for GLP-1 Users

GLP-1 · Wilmington

MENU - ORDER AI Announces Global Expansion with New Multilingual Capabilities, Supporting WHO Guidance on Dietary Needs for GLP-1 Users

67% Center coverage: 15 sources

New multilingual capabilities expand access to real-time GLP-1 dining guidance as WHO highlights the importance of protein-focused nutrition.See the Story

Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting

Shanghai, China · Shanghai

Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting

58% Center coverage: 14 sources

SHANGHAI, Dec. 6, 2025 /PRNewswire/ -- Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated, first-in-human study of GT801, a T-LNP/mRNA–based in vivo…See the Story

Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients with Treatment-Naïve NRG1+NSCLC: Updated eNRGy Trial Results Presented at IASLC-ASCO NACLC

Maryland · Maryland

Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients with Treatment-Naïve NRG1+NSCLC: Updated eNRGy Trial Results Presented at IASLC-ASCO NACLC

62% Center coverage: 13 sources

LEXINGTON, Mass., Dec. 6, 2025 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company, announced new data from a post hoc analysis of the Phase 2 eNRGy trial (NCT02912949) evaluating zenocutuzumab in patients with treatment-naïve non-small cell lung…See the Story

Breaking News Topics Related to miltonindependent.com